DCVAC Product Candidates

SOTIO’s DCVAC is a cell therapy platform designed to improve efficacy compared to earlier generations of dendritic cell therapies by targeting multiple antigens and applying
an immune-stimulatory technique. The DCVAC platform has produced candidates that have shown a significant overall survival benefit across multiple independent Phase 2 trials with a favorable safety profile.


DCVAC/OvCa is an autologous immunotherapy for the treatment of epithelial ovarian cancer investigated in four Phase 2 trials; a pivotal international Phase 3 trial is currently in preparation. For more information about clinical trials evaluating DCVAC/OvCa, please see the section CLINICAL TRIALS.

Clinical results to date indicate a survival benefit in maintenance setting after first line chemotherapy in women with newly-diagnosed epithelial ovarian carcinoma, as well as in combination with second-line chemotherapy in women with first relapse of platinum-sensitive epithelial ovarian carcinoma.


DCVAC/PCa is an autologous immunotherapy being developed for the treatment of metastatic castration-resistant prostate cancer. For more information about the DCVAC/PCa clinical trials, please see the section CLINICAL TRIALS


DCVAC/LuCa is an autologous immunotherapy currently being investigated in a Phase 1/2 clinical trial for the treatment of advanced metastatic non-small cell lung carcinoma (NSCLC). For more information about the DCVAC/LuCa clinical trial, please see the section CLINICAL TRIALS.